• P95 appoints Henk Hoornaert as Chief Commercial Officer

    Wednesday November 17th 2021

  • New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer

    Tuesday November 16th 2021

  • Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis

    Monday November 15th 2021

  • Biotalys’ first biocontrol Evoca™ demonstrated to be excellent new tool for growers in 2021 independent field trials

    Monday November 15th 2021

  • OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME)

    Monday November 15th 2021

  • Belgium has all the ingredients to be a top country for data science in health – but we have to act now!

    Monday November 15th 2021

  • GSK and imec to collaborate on disruptive innovation in pharma

    Tuesday November 9th 2021

  • reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program

    Monday November 8th 2021

  • Your news here?

  • Agomab Therapeutics to acquire Origo Biopharma

    Thursday October 28th 2021

  • Thirona closes financing round with HERAN Partners and Borski Fund

    Thursday October 28th 2021

  • reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

    Thursday October 21st 2021

Strategic Partners